PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock
PTC Therapeutics VP Mark Elliott Boulding sold 2,813 shares of the company's stock on August 17th for a total of $204,139.41, reducing his ownership by 2.60%. This sale was part of a pre-arranged Rule 10b5-1 trading plan and follows earlier sales in June and July. The company's stock traded up by $1.04 to $73.67, with a market capitalization of $6.15 billion, and recently beat earnings and revenue estimates.
PTC Therapeutics (NASDAQ: PTCT) holder plans 50,000-share resale
A holder of PTC Therapeutics (NASDAQ: PTCT) plans to resell 50,000 common shares. The shares will be sold by Michael Schmertzler through Section Six Partners, LP, via Merrill Lynch on NASDAQ. These shares were acquired on July 4, 2012, and the sale is being conducted under Rule 144, which outlines conditions for the legal resale of restricted or insider-held shares.
PTC Therapeutics (NASDAQ: PTCT) CLO sells 2,813 shares under 10b5-1 plan
Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (NASDAQ: PTCT), exercised stock options for 2,813 shares at $25.69 per share and subsequently sold these shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. These transactions were executed under a pre-adopted Rule 10b5-1 plan. Following the sale, Boulding still holds 16,876 stock options from the same grant and 105,272 shares of common stock.
The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920
PTC Therapeutics' bull case is potentially shifting due to positive renal data and regulatory progress for its gene therapy, ST-920, highlighted by a recent special call. This development underscores PTC's growing focus on rare disease gene therapies and portfolio diversification beyond its current commercial base. While the immediate future still relies on existing product performance, ST-920's advancement offers a new pillar for the company's long-term investment narrative and financial outlook.
PTC Therapeutics (NASDAQ: PTCT) insider lines up $201,692 share sale
An insider at PTC Therapeutics (NASDAQ: PTCT), Mark Boulding, has filed a Form 144 notice to sell 2,813 shares of common stock valued at $201,692.10. This planned sale is scheduled for August 17, 2026, following a stock option exercise. The filing also revealed previous sales by Boulding, including 10,522 shares on June 17, 2026, and 5,079 shares on July 6, 2026.
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal
PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset for $111 million in a bankruptcy auction, with potential additional payments of up to $100 million based on U.S. regulatory milestones. This acquisition aims to leverage PTC's existing global commercial and regulatory infrastructure to add a potential one-time treatment for Fabry disease to its rare disease portfolio. The ST-920 program, an AAV gene replacement therapy, is based on promising Phase I/II STAAR study results, showing positive eGFR slope and sustained alpha-galactosidase A activity, and has received multiple FDA designations.
Assenagon Asset Management S.A. Has $563,000 Holdings in PTC Therapeutics, Inc. $PTCT
Assenagon Asset Management S.A. significantly reduced its stake in PTC Therapeutics, Inc. by 88.8% in Q2, retaining 6,899 shares valued at $563,000, while other institutions like Segall Bryant & Hamill increased their positions. Despite insider selling worth $15.65 million, PTC Therapeutics reported strong Q2 revenue of $360.52 million, up 101.5% year-over-year, and adjusted EPS of $0.92, significantly beating analyst estimates. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $98.55.
PTC Therapeutics Is Maintained at Overweight by Barclays
Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT
Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate Buy" and a target price of $98.55. Despite strong quarterly earnings that exceeded estimates, insiders sold a combined $15.65 million of stock.
PTCT Maintained by Barclays -- Price Target Raised to $122
Barclays has maintained an "Overweight" rating for PTC Therapeutics (PTCT) and increased its price target to $122.00 from $120.00. Despite this positive analyst outlook, GuruFocus indicates the stock is significantly overvalued at $71.52 against a GF Value of $37.55, with a mixed GF Score of 53/100 and negative insider activity. Investors are advised to exercise caution due to the valuation challenges and mixed signals from institutional and insider investors.
PTC takes a chance on Sangamo’s Fabry disease gene therapy
PTC Therapeutics has acquired an experimental gene therapy for Fabry disease, ST-920, from the bankrupt Sangamo Therapeutics for up to $211 million. Analysts view this as a risky but potentially high-reward move, as the treatment is nearing FDA approval and could offer a superior option for the $2 billion Fabry disease market. PTC plans to complete the FDA application in the fourth quarter and aims for a 2027 launch, leveraging existing promising research results and a lower acquisition cost due to Sangamo's bankruptcy.
PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy
PTC Therapeutics has won a bankruptcy auction for Sangamo Therapeutics' gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, with a bid of $111 million upfront and up to $100 million in milestone payments. This acquisition expands PTC's rare disease pipeline, bringing a therapy already in the regulatory review process with an anticipated FDA approval by 2027. The deal comes after Sangamo Therapeutics filed for Chapter 11 bankruptcy following failed attempts to find strategic alternatives for its programs.
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy
PTC Therapeutics (PTCT) is acquiring ST-920, a BLA-stage Fabry gene therapy, from Sangamo Therapeutics for $111 million upfront and up to $100 million in milestones. This acquisition aims to expand PTC's rare disease portfolio and facilitate accelerated FDA approval by late 2026, with a potential launch in 2027. Clinical data from the STAAR study supports the therapy's efficacy in improving renal function and providing durable enzyme activity for Fabry disease.
Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners
Bankrupt Sangamo Therapeutics secured at least $163 million from an asset sale, with Eli Lilly and PTC Therapeutics emerging as the primary buyers. This auction marks a crucial step in winding down Sangamo's 31-year history, a company that spent $1.7 billion on drug technologies but failed to bring any treatment to market. The sale helps resolve the company's financial obligations.
How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing
This article analyzes Ptc Therapeutics Inc. (PTCT) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias, and details specific position, momentum breakout, and risk hedging strategies with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels.
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment
PTC Therapeutics (PTCT) stock rose 6.7% after the company reported a profitable second quarter of 2026, exceeding revenue expectations with $360.52 million and achieving a net income of $83.5 million. The company also raised its full-year 2026 total revenue outlook to $1.18 billion–$1.28 billion and appointed Hege Sollie-Zetlmayer to its board, reinforcing investor confidence in its rare disease growth strategy. This positive news helps support the company's investment narrative, though product concentration and regulatory uncertainties remain key factors for long-term assessment.
Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment
PTC Therapeutics (PTCT) saw its stock rise by 6.7% following a strong second quarter in 2026, reporting US$360.52 million in revenue and US$83.5 million in net income. The company also raised its full-year 2026 revenue outlook to between US$1.18 billion and US$1.28 billion and appointed Hege Sollie-Zetlmayer to its board of directors. These positive developments are influencing investor perception of PTC Therapeutics's growth potential and governance.
Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped?
PTC Therapeutics reported a significant shift from a loss to a net income of US$83.5 million in Q2 2026 and raised its full-year revenue guidance to US$1.18b-US$1.28b. Despite a recent share price increase of 9.56% over the past week, the stock is considered 23% undervalued, with a fair value estimate of $96.93 compared to its current price of $74.63. The company's recent approvals for Sephience in the U.S. and Europe for PKU are expected to drive substantial market share and accelerate profitability, although risks related to adoption and regulatory setbacks remain.
Don't Ignore The Insider Selling In PTC Therapeutics
This article highlights recent insider selling at PTC Therapeutics (NASDAQ: PTCT), specifically noting that insiders sold shares worth US$1.4 million over the last year, with no purchases. Despite this, the company's market capitalization has increased, suggesting the insider selling might be opportunistic rather than indicative of business decline. Investors are advised to consider the context of insider transactions alongside other financial analysis.
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
PTC Therapeutics, Inc. (PTCT) has received a "HOLD" investment rating from Argus, with a target price lowered to $79.00 from a current price of $73.31. The report highlights medium subratings for industry, financial strength, and value, while management, safety, and growth subratings are low. This assessment suggests a cautious outlook for the company's stock performance.
Have PTC Therapeutics Insiders Been Selling Stock?
PTC Therapeutics' CEO Matthew Klein recently sold US$706k worth of shares, reducing his holding by 6.2%. This follows an earlier sale where shares were sold below the current market price. While the company boasts 2.5% insider ownership, there have been no insider purchases over the last year, suggesting caution despite alignment of interests.
Have PTC Therapeutics Insiders Been Selling Stock?
PTC Therapeutics' CEO & Director, Matthew Klein, recently sold a portion of his shares for US$706k, reducing his holding by 6.2%. While this sale and an earlier one were below the current market price, indicating a potential negative signal, insiders still maintain significant ownership (2.5% or US$151m) in the company. The article suggests that despite high insider ownership, the history of share sales warrants some caution for investors.
Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold
Zacks Research has downgraded PTC Therapeutics (NASDAQ:PTCT) from a "Strong Buy" to a "Hold" rating, despite the company's recent strong financial performance. PTC Therapeutics exceeded expectations in its latest quarterly results with an EPS of $0.92 and revenue of $360.52 million, a 101.5% year-over-year increase. The broader analyst consensus remains a "Moderate Buy" with an average target price of $98.09, but insiders have sold a significant amount of shares while institutional investors have increased their positions.
PTC Therapeutics CEO Klein sells $705,722 in company stock
Matthew B. Klein, CEO of PTC Therapeutics, sold 10,292 shares of company stock for $705,722 to cover tax withholding obligations related to RSU vesting. Following the sale, Klein beneficially owns 383,868 shares. Analysts predict the company will be profitable in 2026, with recent Q2 2026 results surpassing expectations due to strong sales of Sephience.
PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes
PTC Therapeutics CEO Matthew B. Klein sold 10,292 shares of common stock on August 4, 2026, at $68.57 per share to cover tax withholding obligations. This automatic "sell-to-cover" transaction was executed under a Rule 10b5-1 trading plan and was tied to the vesting of 25,000 Restricted Stock Units (RSUs). Following the sale, Klein directly holds 383,868 shares of the company's common stock.
PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System
California State Teachers Retirement System increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 23.5% in the first quarter, now owning 84,320 shares. Several other major institutions, including Vanguard, Janus Henderson, and State Street, also expanded their positions in the biopharmaceutical company. Despite some insider selling, the stock maintains a "Moderate Buy" consensus rating from analysts, who forecast average earnings per share of 1.3 for the current year.
PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases
Analyst price targets for PTC Therapeutics (PTCT) are increasing, with several firms raising their targets due to strong Sephience performance and a promising broader pipeline. This has led to a slight increase in the fair value estimate for PTCT, although some analysts maintain a more balanced view given the moderating growth of Sephience in the U.S.
PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144
Matthew Klein, an insider at PTCT Therapeutics, has filed to sell 10,292 shares of common stock under Rule 144, valued at $705,754.35. These shares, which vested on August 3, 2026, were granted as compensation and are planned for sale on or after August 4, 2026, via Fidelity Brokerage Services LLC on NASDAQ. Klein also previously sold 12,572 shares on May 14, 2026, for $917,129.43.
Top 3 Health Care Stocks You'll Regret Missing This Quarter
This article identifies three oversold healthcare stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT), and Indivior Pharmaceuticals (INDV), which recently announced a merger with Supernus Pharmaceuticals. These companies are highlighted due to their Relative Strength Index (RSI) being below 30, indicating they may be undervalued. The piece details recent events impacting each stock, such as leadership changes, quarterly results, and merger announcements, alongside their current price actions and RSI values.
PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PTC Therapeutics (PTCT) has seen a 20.3% loss in stock value over the past four weeks, but indicators suggest a potential trend reversal. The stock is currently in oversold territory with an RSI reading of 27.14, and Wall Street analysts have significantly raised their earnings estimates for the company. Furthermore, PTCT holds a Zacks Rank #2 (Buy), indicating a strong potential for a near-term turnaround.
Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCT
Empowered Funds LLC significantly reduced its stake in PTC Therapeutics, Inc. by selling 192,506 shares, retaining 57,906 shares valued at $3.95 million. This divestment occurred despite other major institutions increasing their holdings and PTC Therapeutics reporting strong quarterly results with EPS of $0.92 and revenue surging 101.5% year over year. Analysts currently hold a "Moderate Buy" consensus with an average price target of $95.75 for the company.
PTC Therapeutics (PTCT) Is Down 11.5% After Raising 2026 Outlook And Boosting Profitability - Has The Bull Case Changed?
PTC Therapeutics reported strong Q2 2026 revenue of US$360.52 million and net income of US$83.5 million, leading to an increased full-year 2026 revenue outlook of US$1.18 billion to US$1.28 billion. Despite this positive financial report, the company's shares experienced an 11.47% weekly decline, prompting questions about the sustainability of its newfound profitability given lower year-to-date revenue compared to the previous year. The article suggests that while profitability improved, the stock might still be overvalued, and investors should scrutinize the evolving business mix and earnings quality.
Price to book forward of PTC Therapeutics, Inc. – BX:P91
This article provides a financial data point for PTC Therapeutics, Inc. (BX:P91), specifically its "Price to book forward." It indicates the value and change for this metric over a specified period. The information is presented within the context of a trading and financial data platform.
PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...
PTC Therapeutics reported record quarterly revenue of $361 million for Q2 2026, driven by strong growth in Sephience revenue and other product sales, leading to a raised full-year product revenue guidance of $850 million to $950 million. The company highlighted positive interim data for its Huntington's disease study and a robust cash position, while also addressing challenges in its Duchenne muscular dystrophy franchise and ongoing regulatory discussions for pipeline candidates. Management expressed confidence in Sephience's continued growth and expansion into international markets.
PTC Therapeutics Q2 Earnings Call Highlights
PTC Therapeutics reported strong Q2 results, raising its 2026 revenue outlook to $1.18 billion to $1.28 billion, driven by the successful launch of Sephience and the durability of its Duchenne muscular dystrophy franchise. The company also provided updates on its international expansion plans for Sephience, pipeline advancements including votoplam and vatiquinone, and its financial position, expecting to reach cash-flow breakeven this year.
PTC Therapeutics (PTCT) Stock Drops As Profit Surge Meets Launch Concentration Risk
PTC Therapeutics (PTCT) experienced a nearly 10% stock drop despite a strong Q2 2026 earnings report, which showed a significant revenue increase and a swing to profitability. The company's optimistic outlook relies on the success of Sephience and its pipeline, with Sephience showing strong adoption. However, bears point to the continued concentration risk on Sephience and future regulatory hurdles for pipeline products as reasons for the stock's decline.
PTC THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $106 FROM $93
Wells Fargo has increased its target price for PTC Therapeutics, Inc. from $93 to $106. This adjustment reflects an updated valuation for the company. The article, sourced from Reuters, includes a disclaimer noting that the content represents the author's opinion and should not be taken as investment advice.
PTC Therapeutics (PTCT) director details stock, options and RSUs
PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer has reported beneficial ownership of 46,526 shares of common stock, including multiple unvested RSU awards. She also holds several stock options, with three currently exercisable for a total of 65,125 shares at various exercise prices. Additional option grants and RSU awards are set to vest over the coming years according to specified schedules.
Press Release: PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTC Therapeutics announced its corporate update and second quarter 2026 financial results. The company provided an overview of its operational performance and key financial metrics for the quarter. This release offers insights into PTC Therapeutics' recent business developments and financial standing.
PTC Therapeutics: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for PTC Therapeutics. The content, however, is minimal and appears to be a placeholder or an incomplete article, containing only privacy protection information and image links.
Earnings call transcript: PTC Therapeutics tops Q2 2026 forecasts on strong sales
PTC Therapeutics reported stronger-than-expected Q2 2026 results, with earnings of $0.92 per share and revenue of $361 million, significantly exceeding Wall Street forecasts. The company attributed its record revenue to strong Sephience sales and raised its full-year 2026 revenue guidance to $1.18 billion-$1.28 billion. Management also provided updates on its pipeline, including its Huntington's disease, ataxia, and NLRP3 inhibitor programs, and discussed international market expansion and financial strength.
PTC Therapeutics: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for PTC Therapeutics. As the provided content is minimal, no further details about the earnings can be extracted or summarized.
PTC Therapeutics (NASDAQ: PTCT) raises 2026 revenue guidance after strong Q2
PTC Therapeutics reported strong Q2 2026 results, achieving a net income of $83.5 million and total revenue of $361 million, significantly improving from a loss in Q2 2025. The company raised its full-year 2026 revenue guidance to $1.18 to $1.28 billion for total revenue and $850 to $950 million for product revenue, driven by strong performance of Sephience and pipeline advancements. PTC also announced a new board appointment and provided updates on its clinical pipeline, including positive data for votoplam and progression of new drug candidates.
PTC Therapeutics Inc (PTCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of PTC Therapeutics Inc (PTCT), highlighting its current price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, offering a comprehensive look at the stock's potential short-term movements. The analysis suggests a neutral signal based on moving averages and other technical indicators.
PTC Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
PTC Therapeutics (PTCT) had 988 employees worldwide as of March 2026, a 28.2% decline since 2023. The company is actively hiring, with 45 active job postings in 2026, and its workforce is primarily concentrated in the United States. The article also details employee distribution by country and department, average salaries, and sentiment.
Renaissance Technologies LLC Sells 74,289 Shares of PTC Therapeutics, Inc. $PTCT
Renaissance Technologies LLC has reduced its stake in PTC Therapeutics, Inc. by 12.2%, selling 74,289 shares and now owning 533,300 shares valued at $36.33 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. PTC Therapeutics' stock opened at $75.39, with a market capitalization of $6.25 billion, and has seen a mix of analyst upgrades resulting in a "Moderate Buy" consensus rating.
PTC Therapeutics, Inc. $PTCT Shares Bought by Rock Springs Capital Management LP
Rock Springs Capital Management LP significantly increased its stake in PTC Therapeutics (PTCT) by 161.5% in the first quarter, now holding 161,798 shares valued at $11 million. This comes as PTC Therapeutics reported strong Q1 revenue of $272.55 million, a 43.5% year-over-year increase, and an adjusted loss of $0.03 per share, beating analyst expectations. Despite a "Moderate Buy" consensus rating and an average price target of $92.29, company insiders sold nearly 199,000 shares worth $16.35 million in the last 90 days.
PTC Therapeutics (PTCT) Receives a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on PTC Therapeutics (PTCT) and set a price target of $85.00. Despite a Strong Buy consensus among analysts with an average price target of $98.64, the company reported a GAAP net loss in its latest quarter, contrasting with a net profit in the previous year. Corporate insider sentiment for PTCT is negative, with increased insider selling activity in the past quarter, including a recent significant sale by the CEO.
PTCT|PTC Therapeutics Inc|Price:75.790|Chg%:-1.030
This article provides a comprehensive stock analysis of PTC Therapeutics Inc (PTCT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis also covers institutional confidence, analyst ratings, and the company's product portfolio, emphasizing its focus on rare disorders and its recent turnaround to profitability.
Orbimed Advisors LLC Has $3.35 Million Stake in PTC Therapeutics, Inc. $PTCT
Orbimed Advisors LLC significantly increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 111.6% in the first quarter, now holding 49,100 shares valued at approximately $3.35 million. This increase comes despite recent insider selling by two executives totaling $3.61 million and other insider sales amounting to $16.35 million over the past three months. Analysts maintain a "Moderate Buy" rating for PTC Therapeutics, with an average price target of $92.29, following the company's strong quarterly revenue growth of 43.5% year-over-year and exceeding earnings expectations.
